J Rowell1, A J Thompson2, J R Guyton1, X Q Lao3, J G McHutchison2, J J McCarthy3, K Patel4. 1. Division of Endocrinology, Department of Medicine, Metabolism and Nutrition, Duke University, Durham, NC, USA. 2. Department of GI/Hepatology Research Program, Duke Clinical Research Institute, Duke University, PO Box 17969, Durham, NC, 27715, USA. 3. Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA. 4. Department of GI/Hepatology Research Program, Duke Clinical Research Institute, Duke University, PO Box 17969, Durham, NC, 27715, USA. keyur.patel@duke.edu.
Abstract
BACKGROUND: The hepatitis C virus (HCV) is known to disrupt lipid metabolism, making serum lipoprotein levels good candidates to explore as markers of HCV disease progression. Assessment of the major apolipoproteins (Apo) and their relationship to hepatic fibrosis remain largely unexplored. METHODS: We compared the levels of total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), and Apo A-I, -B, -C-III, and -E between patients with cleared versus active infection (n = 83), and between those chronically infected patients (n = 216) with advanced versus mild-moderate hepatic fibrosis (METAVIR stage F3-4 vs. F0-2) using multiple logistic regression. RESULTS: Apo C-III levels were 25% higher in subjects with cleared infection versus those with active infection (p = 0.009). Low levels of Apo C-III (p = 1.3 × 10(-5)), Apo A-I (p = 2.9 × 10(-5)), total cholesterol (p = 5.0 × 10(-4)), LDL-C (p = 0.005), and HDL-C (p = 2.0 × 10(-4)) were associated with advanced fibrosis in univariate analyses. Multivariable analysis revealed Apo C-III as the most significant factor associated with advanced fibrosis (p = 0.0004), followed by age (p = 0.013) and Apo A-I (p = 0.022). Inclusion of both Apo C-III and Apo A-I in a model to predict advanced fibrosis improved the area under the receiver operator curve only modestly. CONCLUSIONS: Relative to other lipoproteins, low serum Apo C-III levels are the most strongly associated with chronic versus cleared infection and decline with increasing severity of hepatic fibrosis. Apo C-III deserves further attention as a possible marker of HCV disease progression.
BACKGROUND: The hepatitis C virus (HCV) is known to disrupt lipid metabolism, making serum lipoprotein levels good candidates to explore as markers of HCV disease progression. Assessment of the major apolipoproteins (Apo) and their relationship to hepatic fibrosis remain largely unexplored. METHODS: We compared the levels of total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), and Apo A-I, -B, -C-III, and -E between patients with cleared versus active infection (n = 83), and between those chronically infectedpatients (n = 216) with advanced versus mild-moderate hepatic fibrosis (METAVIR stage F3-4 vs. F0-2) using multiple logistic regression. RESULTS:Apo C-III levels were 25% higher in subjects with cleared infection versus those with active infection (p = 0.009). Low levels of Apo C-III (p = 1.3 × 10(-5)), Apo A-I (p = 2.9 × 10(-5)), total cholesterol (p = 5.0 × 10(-4)), LDL-C (p = 0.005), and HDL-C (p = 2.0 × 10(-4)) were associated with advanced fibrosis in univariate analyses. Multivariable analysis revealed Apo C-III as the most significant factor associated with advanced fibrosis (p = 0.0004), followed by age (p = 0.013) and Apo A-I (p = 0.022). Inclusion of both Apo C-III and Apo A-I in a model to predict advanced fibrosis improved the area under the receiver operator curve only modestly. CONCLUSIONS: Relative to other lipoproteins, low serum Apo C-III levels are the most strongly associated with chronic versus cleared infection and decline with increasing severity of hepatic fibrosis. Apo C-III deserves further attention as a possible marker of HCV disease progression.
Entities:
Keywords:
Apolipoprotein AI; Apolipoprotein C-III; Fibrosis; Hepatitis C virus
Authors: Xavier Forns; Sergi Ampurdanès; Josep M Llovet; John Aponte; Llorenç Quintó; Eva Martínez-Bauer; Miquel Bruguera; Jose Maria Sánchez-Tapias; Juan Rodés Journal: Hepatology Date: 2002-10 Impact factor: 17.425
Authors: C Fernández-Miranda; G Castellano; C Guijarro; I Fernández; N Schöebel; S Larumbe; T Gómez-Izquierdo; A del Palacio Journal: Am J Gastroenterol Date: 1998-10 Impact factor: 10.864
Authors: Jean Michel Petit; Muriel Benichou; Laurence Duvillard; Valerie Jooste; Jean Baptiste Bour; Anne Minello; Bruno Verges; Jean Marcel Brun; Philippe Gambert; Patrick Hillon Journal: Am J Gastroenterol Date: 2003-05 Impact factor: 10.864
Authors: Jessica D Tenenbaum; Victoria Christian; Melissa A Cornish; Rowena J Dolor; Ashley A Dunham; Geoffrey S Ginsburg; Virginia B Kraus; John G McHutchison; Meredith L Nahm; L Kristin Newby; Laura P Svetkey; Krishna Udayakumar; Robert M Califf Journal: Am J Transl Res Date: 2012-07-23 Impact factor: 4.060
Authors: Eric G Meissner; Yu-Jin Lee; Anu Osinusi; Zayani Sims; Jing Qin; Dan Sturdevant; John McHutchison; Mani Subramanian; Maureen Sampson; Susanna Naggie; Keyur Patel; Alan T Remaley; Henry Masur; Shyam Kottilil Journal: Hepatology Date: 2015-01-28 Impact factor: 17.425
Authors: Susanna Naggie; Keyur Patel; Lan-Yan Yang; Shein-Chung Chow; Victoria Johnson; John R Guyton; Andrew J Muir; Mark Sulkowski; Charles Hicks Journal: Open Forum Infect Dis Date: 2015-05-12 Impact factor: 3.835